Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient

Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient

Marie Fournier,1 Chieh-I Chen,2 Andreas Kuznik,2 Clare Proudfoot,3 Usha G Mallya,4 Kaleb Michaud5,6 1Health Economics & Value Assessment, Sanofi France, Chilly-Mazarin, France; 2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 3Sanofi, Guildford, UK; 4Sanofi, Bridgewater, NJ, USA; 5Unive...

Full description

Bibliographic Details
Main Authors: Fournier M, Chen C, Kuznik A, Proudfoot C, Mallya UG, Michaud K
Format: Article
Language:English
Published: Dove Medical Press 2019-02-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
Treatment costs
disease-modifying anti-rheumatic drug
IL-6 inhibitor
rheumatoid arthritis
Online Access:https://www.dovepress.com/sarilumab-monotherapy-compared-with-adalimumab-monotherapy-for-the-tre-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/sarilumab-monotherapy-compared-with-adalimumab-monotherapy-for-the-tre-peer-reviewed-article-CEOR

Similar Items